Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy  You Lu,

Published byNatalie Glenn Modified over 5 years ago

Similar presentations

Presentation on theme: "P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy  You Lu,"— Presentation transcript:

1 P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy  You Lu, Jianying Zhou, Chin-Hee Chung, Elizabeth Masters, Keith Wilner, Paulina Selaru, Yiyun Tang, Yi Long Wu  Journal of Thoracic Oncology  Volume 12, Issue 1, (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, DOI: (10. 1016/j. jtho. 2016. 11
Copyright © Terms and Conditions

Download ppt "P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy  You Lu,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)

Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)
PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)  Gilberto De Castro,

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)  Gilberto De Castro,
P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4)  Daniel Shao-Weng.

P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4)  Daniel Shao-Weng.
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.
SC09.04 Radiotherapy in China

SC09.04 Radiotherapy in China
Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)

Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations  Ee Ke, Zhihong.

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations  Ee Ke, Zhihong.
MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC  Rafal Dziadziuszko,

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC  Rafal Dziadziuszko,
P1.07-038 Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas  Hao-Ran Zhai, Jia-Tao Zhang,

P Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas  Hao-Ran Zhai, Jia-Tao Zhang,
P2.04-054 Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Similar presentations

Ads by Google